NIKKEI 225
39,099.44 +294.79 (+0.76%) HANG SENG
18,101.25 +73.54 (+0.41%) CRUDE OIL
81.67 +0.04 (+0.05%) GOLD FUTURES
2,339.50 -4.90 (-0.21%) DOW
39,411.21 +260.88 (+0.67%) Bitcoin GBP
48,306.29 -912.44 (-1.85%)
REGN Jul 2024 890.000 call
| Previous close | 115.00 |
| Open | N/A |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 890.00 |
| Expiry date | 2024-07-05 |
| Day's range | 115.00 - 115.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
Simply Wall St.Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
